Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination | VBI Vaccines

Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination

February 8, 2021 | Publications

View More

February 2, 2021

VBI Vaccines Announces U.S. FDA Acceptance of BLA Filing for VBI’s 3-Antigen Prophylactic Hepatitis B Vaccine

January 21, 2021

VBI Vaccines Announces Progress of Coronavirus Vaccine Program

January 15, 2021

VBI Vaccines Announces Publication of Results from a Phase 4 Study of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine in Vaccine

December 23, 2020

VBI Vaccines Announces European Medicines Agency Acceptance of Marketing Authorization Application (MAA) for 3-Antigen Prophylactic Hepatitis B Vaccine

December 7, 2020

VBI Vaccines Selects Syneos Health as Commercialization Partner for Prophylactic 3-Antigen Hepatitis B Vaccine

December 2, 2020

VBI Vaccines to Discuss Hepatitis B Portfolio in Virtual Fireside Chat Hosted by Raymond James

December 1, 2020

VBI Vaccines Announces Submission of Biologics License Application to FDA for 3-Antigen Prophylactic Hepatitis B Vaccine

November 23, 2020

VBI Vaccines Announces Submission of Marketing Authorization Application for 3-Antigen Prophylactic Hepatitis B Vaccine to the European Medicines Agency

Sign-up for Our Distribution List to Receive the Latest News and Updates from VBI